Overview: Napsin A Immunohistochemistry TestIntroduction: The Napsin A Immunohistochemistry Test detects napsin A protein to diagnose lung adenocarcinoma, causing cough or chest pain. Following 2023 NCCN guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected lung adenocarcinoma.
Other Names: Napsin A IHC Assay, Lung Adenocarcinoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Napsin A testing began in the 2000s with lung cancer research. Immunohistochemistry-based methods improved diagnostic precision for lung adenocarcinoma.
Purpose: Detects napsin A to diagnose lung adenocarcinoma, guides treatment, and evaluates patients with cough or chest pain.
Test Parameters: 1. Napsin A Protein
Pretest Condition: No fasting required. Collect tissue via lung biopsy or surgical resection. Report history of cough, chest pain, or lung cancer symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document cough, chest pain, weight loss, or family history of lung cancer. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect napsin A in lung tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for lung adenocarcinoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive napsin A staining confirms lung adenocarcinoma, guiding surgery or chemotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult an oncologist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: TTF-1 IHC, CK7 IHC, or PET-CT to confirm lung adenocarcinoma diagnosis.
Test Limitations: Not specific to lung adenocarcinoma; other tumors may express napsin A. Clinical correlation is needed.
References: NCCN Lung Cancer Guidelines, 2023; American Journal of Surgical Pathology, Bishop JA, 2022.
